Women's health company Bonafide released its sixth annual "State of Menopause" survey on July 15, 2026, polling more than 2,000 symptomatic women aged 40–64, with trade coverage building through the end of the month. The through-line of the 2026 edition: the symptoms doing the most damage aren't the ones the category markets against. Anxiety, depression and panic attacks were rated the most disruptive symptoms, ahead of hot flashes. Sixty percent of respondents reported mental health impacts and 50% said menopause negatively affected cognitive function.

Why It Matters

The menopause market has been sized, funded, and marketed largely around vasomotor symptoms — hot flashes and night sweats — because they are legible, measurable, and easy to build a product claim around. This survey says the disruption is concentrated in mood and cognition, where the evidence bar is higher, the regulatory path is murkier, and supplements have historically overpromised. That's a real problem for a category currently full of "menopause" SKUs with thin clinical backing, and an opening for anyone willing to fund actual trials. The workplace data is the sleeper: a 48% self-reported income drop and 7% accommodation awareness suggest employer-benefits distribution — the channel femtech has bet heavily on — is not reaching the people it was built for. And the perimenopause-worse-than-menopause finding points product roadmaps five to ten years earlier than most brands currently target, toward exactly the diagnostic gap that continuous hormone-monitoring startups like Kāhu SiliconBio, Clair Health and Eli Health are racing to fill.

The workplace numbers are the ones executives should read twice. Fifty-six percent noticed a decline in motivation, 48% reported a drop in income, and 27% concealed symptoms from their employers. Only 7% were aware of any workplace menopause accommodations at all — and that figure was down from the prior year's survey, despite two years of menopause-benefit announcements from large employers and a wave of menopause-focused startups selling into HR.

Recognition remains the bottleneck. Seventy-one percent said they didn't recognize their symptoms as menopause-related at first, and 62% said talking to other women is what made them realize they weren't imagining the experience. Nearly 40% identified affirmation — not information, not treatment — as the most valuable outcome of those conversations, which is why so many end up on Reddit threads and with social-media influencers rather than clinicians. Notably, women in perimenopause reported nearly every symptom and challenge at higher rates than women already through menopause, pointing the unmet need at the earlier, harder-to-diagnose end of the transition.

Bonafide's own read on where the category goes next was blunt about the marketing status quo. "It's no longer enough to simply market products to women over 40 or add 'menopause' to the label," Bonafide's Jamieson told SupplySide Supplement Journal. "Women are looking for evidence-backed solutions that address the symptoms they're actually experiencing, and they expect companies to invest in research and clinical studies on the menopausal women's body and biology." Her forecast: "Women are asking for support earlier, and I expect innovation to follow."

The findings rhyme with a busy month of menopause research. Johns Hopkins' Bloomberg School published a systematic review of 89 studies on July 21 concluding menopause care is fragmented and inadequate worldwide, and Flo Health released global data in late July on the severity of perimenopausal mental health symptoms. The consistency across independent datasets is itself notable — and so is the caveat that Bonafide sells menopause supplements and commissioned the survey.

Sources

Update — 2026-08-01

{Initial entry — story first created.}